

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT2993554

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
XIAOMING ZHANG	08/20/2014
EDWARD F. SCHNIPPER	08/20/2014
ANDREW J. PERLMAN	08/20/2014
JAMES W. LARRICK	08/20/2014
RECEIVING PARTY DATA	
Name:	TIGERCAT PHARMA, INC.
Street Address:	400 OYSTER POINT BLVD.
Internal Address:	SUITE 202
City:	SOUTH SAN FRANCISCO
State/Country:	CALIFORNIA
Postal Code:	94080
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14312942
CORRESPONDENCE DATA	
Fax Number:	(703)391-2901
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	703-391-2900
Email:	ptonotices@marburylaw.com
Correspondent Name:	THE MARBURY LAW GROUP, PLLC
Address Line 1:	11800 SUNRISE VALLEY DRIVE
Address Line 2:	15TH FLOOR
Address Line 4:	RESTON, VIRGINIA 20191
ATTORNEY DOCKET NUMBER:	3002-001CIP
NAME OF SUBMITTER:	LINDA KENAH
SIGNATURE:	/Linda Kenah/
DATE SIGNED:	08/22/2014
Total Attachments: 2	
source=3002_001CIP_Assignment#page1.tif	

WORLD-WIDE ASSIGNMENT AND AGREEMENT

WHEREAS, Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, and James W. LARRICK (hereinafter referred to singly and collectively as "ASSIGNOR") have invented a certain invention entitled ***USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS*** for which a non-provisional application for United States Letters Patent was filed on June 24, 2014, as Application No. 14/312,942, and which is a continuation- in-part of United States Patent Application No. 13/925,509 filed June 24, 2013, and which application also claims benefit of United States Provisional Patent Application No. 61/838,784, filed June 24, 2013.

WHEREAS, Tigercat Pharma, Inc., a corporation, having its office at 400 Oyster Point Blvd., Suite 202, South San Francisco, CA 94080, U.S.A.(hereinafter referred to as "ASSIGNEE") is desirous of acquiring the entire interest therein world-wide;

NOW THEREFORE, in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR has sold, assigned, and transferred, and by these presents hereby sells, assigns, and transfers, unto ASSIGNEE, its successors and assigns, the full and exclusive right, title, and interest in and to (a) the above-identified invention or inventions and all improvements and modifications thereof, (b) the above-identified provisional application and all other applications for Letters Patent of the United States and countries foreign thereto for the above-identified invention or inventions and all improvements and modifications thereof, (c) all Letters Patent which may issue from said applications in the United States and countries foreign thereto, (d) all divisions, continuations, reissues, and extensions of said applications and Letters Patent, and (e) the right to claim for any of said applications the full benefits and priority rights under the International Convention and any other international agreement to which the United States adheres; such right, title, and interest to be held and enjoyed by ASSIGNEE, its successors and assigns, to the full end of the term or terms for which any and all such Letters Patent may be granted as fully and entirely as would have been held and enjoyed by ASSIGNOR had this Assignment not been made.

ASSIGNOR HEREBY AUTHORIZES AND REQUESTS the Commissioner of Patents and Trademarks to issue said Letters Patent to ASSIGNEE as assignee of the entire interest, for the sole use and benefit of ASSIGNEE, its successors and assigns.

ASSIGNOR HEREBY AGREES (a) to communicate to ASSIGNEE, its successors and assigns, or their representatives or agents, all facts and information known or available to ASSIGNOR respecting said invention or inventions, improvements, and modifications including evidence for interference, reexamination, reissue, opposition, revocation, extension, or infringement purposes or other legal, judicial, or administrative proceedings, whenever requested by ASSIGNEE; (b) to testify in person or by affidavit as required by ASSIGNEE, its successors and assigns, in any such proceeding in the United States or a country foreign thereto; (c) to execute and deliver, upon request by ASSIGNEE, all lawful papers including, but not limited to, original, divisional, continuation, and reissue applications, renewals, assignments, powers of attorney, oaths, affidavits, declarations, depositions; and (d) to provide all reasonable assistance to

ASSIGNEE, its successors and assigns, in obtaining and enforcing proper title in and protection for said invention or inventions, improvements, and modifications under the intellectual property laws of the United States and countries foreign thereto.

ASSIGNOR HEREBY REPRESENTS AND WARRANTS that ASSIGNOR has the full and unencumbered right to sell, assign, and transfer the interests sold, assigned, and transferred herein, and that ASSIGNOR has not executed and will not execute any document or instrument in conflict herewith.

ASSIGNOR HEREBY GRANTS to the law firm of **The Marbury Law Group PLLC** the power and authority to insert in this Assignment any further identification which may be necessary or desirable to comply with the rules of the U.S. Patent and Trademark Office for recordation of this Assignment.

ASSIGNOR UNDERSTANDS AND AGREES that the attorneys and agents of the law firm of **The Marbury Law Group PLLC** do not personally represent ASSIGNOR or ASSIGNOR's legal interests, but instead represent the interests of ASSIGNEE; since said attorneys and agents cannot provide legal advice to ASSIGNOR with respect to this Assignment, ASSIGNOR acknowledges its right to seek its own independent legal counsel.

NAMES AND SIGNATURES OF INVENTORS (date required)			
Name:	Signature:	Date:	Witnessed by:
Xiaoming ZHANG		08/20/2014	
Edward F. SCHNIPPER		08/20/2014	
Andrew J. PERLMAN		08/20/2014	
James W. LARRICK		08/20/2014	

Note: Witness signature not required, but generally advisable.